Entrada Therapeutics (TRDA) furnishes Q3 2025 results and corporate update press release

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. filed a current report describing that it announced financial results for the quarter ended September 30, 2025, along with other corporate updates. These results and updates are provided in a press release dated November 6, 2025, which is included as an exhibit to the report.

The press release is furnished, not filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001689375false00016893752025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

ENTRADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-40969			81-3983399
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

One Design Center Place
Suite 17-500
Boston, MA						02210
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (857) 520-9158

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TRDA

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Entrada Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025 and other corporate updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits.

The following exhibit relating to Item 2.02 of this Form 8-K shall be deemed to be furnished and not filed:

99.1			Press Release issued by Entrada Therapeutics, Inc. on November 6, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Entrada Therapeutics, Inc.
Date: November 6, 2025						/s/ Dipal Doshi
						Dipal Doshi
						Chief Executive Officer

FAQ

What did Entrada Therapeutics (TRDA) disclose in this 8-K filing?

Entrada Therapeutics disclosed that it announced financial results for the quarter ended September 30, 2025, and other corporate updates, with details contained in a press release furnished as Exhibit 99.1 to the report.

Which period do the disclosed Entrada Therapeutics (TRDA) results cover?

The disclosed results cover Entrada Therapeutics’ financial performance for the quarter ended September 30, 2025. The company announced these quarterly results on November 6, 2025, and furnished the related press release as an exhibit to the report.

How did Entrada Therapeutics (TRDA) provide its Q3 2025 results to investors?

Entrada Therapeutics provided its Q3 2025 results through a press release dated November 6, 2025. That press release, which includes the detailed figures and corporate updates, is furnished as Exhibit 99.1 to the current report.

Is the Entrada Therapeutics (TRDA) earnings press release considered filed with the SEC?

The press release is furnished, not filed, with the SEC. This means it is not automatically subject to Section 18 liabilities or incorporated into other securities law filings unless specifically incorporated by reference.

What exhibit did Entrada Therapeutics (TRDA) attach with its Q3 2025 8-K?

Entrada Therapeutics attached Exhibit 99.1, a press release issued on November 6, 2025, containing its quarterly financial results and corporate updates, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Entrada Therapeutics (TRDA) Form 8-K for Q3 2025 results?

The Form 8-K was signed on behalf of Entrada Therapeutics by Dipal Doshi. The signature block identifies Dipal Doshi as the company’s Chief Executive Officer, acting as the duly authorized signatory for the registrant.